Zealand Pharma
ZEAL.CO
#2185
Rank
A$11.02 B
Marketcap
$156.05
Share price
4.23%
Change (1 day)
109.99%
Change (1 year)

P/E ratio for Zealand Pharma (ZEAL.CO)

P/E ratio as of November 2024 (TTM): -36.9

According to Zealand Pharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -36.8507. At the end of 2022 the company had a P/E ratio of -7.70.

P/E ratio history for Zealand Pharma from 2010 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-7.7026.06%
2021-6.11-39.1%
2020-10.0-26.19%
2019-13.6-410.31%
20184.38-150.96%
2017-8.59-48.84%
2016-16.8-44.45%
2015-30.29.66%
2014-27.6278.57%
2013-7.28-113.64%
201253.4-171.22%
2011-75.0605%
2010-10.6

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.